Corneal collagen cross-linking for bacterial infectious keratitis

Davis, Shadi A; Bovelle, Renee; Han, Genie; Kwagyan, John

doi:10.1002/14651858.cd013001.pub2

Cited by 18 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, there was no significant difference between the epithelial defect size, rates of adverse events, and CDVA at final follow-up. A Cochrane systematic review of 3 trials totaling 59 eyes reported no real benefit with PACK-CXL compared with standard antibiotic therapy 59. It concluded that there was low-quality evidence on the effectiveness of PACK-CXL for bacterial keratitis due to the clinical heterogeneity of outcomes and small sample sizes.…”

Section: Alternative Use Of Crosslinkingmentioning

confidence: 99%

Corneal Crosslinking: Present and Future

Angelo¹,

Boptom²,

McGhee³

et al. 2022

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

Keratoconus is a progressive corneal thinning disorder that can lead to vision loss. In the last 2 decades, corneal crosslinking (CXL) has emerged as an effective method to halt the progression of keratoconus and reduce the number of patients requiring keratoplasty. The procedure has been adopted globally and has evolved to become a part of combination treatments to regularize the cornea and improve visual outcomes. CXL has even been extrapolated in managing other ocular pathologies such as progressive myopia, infectious keratitis, and bullous keratopathy. This review aims to summarize the current role of CXL in keratoconus and its alternative uses, and provide insights into future developments in this fast-developing field.

show abstract

Section: Alternative Use Of Crosslinkingmentioning

confidence: 99%

Corneal Crosslinking: Present and Future

Angelo¹,

Boptom²,

McGhee³

et al. 2022

Asia-Pacific Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Shanks proposed the use of predatory bacteria to eliminate ocular pathogens as method to treat ocular infections [ 52 , 53 ]. Photoactivated chromophore for collagen cross-linking of the cornea [ 54 ] and rose Bengal photodynamic antimicrobial therapy [ 55 ] have been tested to treat severe, progressive infectious keratitis.…”

Section: Alternative Anti-infective Delivery and Therapymentioning

confidence: 99%

Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections

et al. 2022

View full text Add to dashboard Cite

The treatment of eye infections is very different than treating other body infections that require systemic anti-infectives. Endophthalmitis, keratitis, conjunctivitis, and other ocular infections are treated with direct injection and with topical drops directly to the infection site. There are no anti-infective susceptibility standards to interpret treatment success, but the systemic standards can be used to guide ocular therapy if the concentration of anti-infective in the ocular tissue is assumed to be higher than the concentration in the blood serum. This Perspective describes: (1) eye infections, (2) diagnostics of eye infections, (3) anti-infective treatment of eye infections, (4) anti-infective resistance of ocular pathogens, and (5) alternative anti-infective delivery and therapy. The data, based on years of clinical and laboratory research, support the premise that ocular infections are less problematic if etiologic agents are laboratory-diagnosed and if prompt, potent, anti-infective therapy is applied. Anti-infective susceptibility should be monitored to assure continued therapeutic success and the possibility of new-found resistance. New delivery systems and therapies may be helpful to better treat future ocular infections.

show abstract

“…Several studies have investigated the use of riboflavin to treat infectious keratitis. Clinical trials have shown that collagen cross-linking (CXL) with UV light-activated riboflavin has a positive role in the treatment of bacterial or fungal keratitis [ 110–113 ]. Conversely, no benefits of the CXL to treat infectious keratitis have been reported [ 114–117 ].…”

Section: Anti-infection Effect Of Exogenous Riboflavinmentioning

confidence: 99%

The promise of endogenous and exogenous riboflavin in anti-infection

et al. 2021

View full text Add to dashboard Cite

To resolve the growing problem of drug resistance in the treatment of bacterial and fungal pathogens, specific cellular targets and pathways can be used as targets for new antimicrobial agents. Endogenous riboflavin biosynthesis is a conserved pathway that exists in most bacteria and fungi. In this review, the roles of endogenous and exogenous riboflavin in infectious disease as well as several antibacterial agents, which act as analogues of the riboflavin biosynthesis pathway, are summarized. In addition, the effects of exogenous riboflavin on immune cells, cytokines, and heat shock proteins are described. Moreover, the immune response of endogenous riboflavin metabolites in infectious diseases, recognized by MHC-related protein-1, and then presented to mucosal associated invariant T cells, is highlighted. This information will provide a strategy to identify novel drug targets as well as highlight the possible clinical use of riboflavin.

show abstract

Corneal collagen cross-linking for bacterial infectious keratitis

Cited by 18 publications

References 45 publications

Corneal Crosslinking: Present and Future

Corneal Crosslinking: Present and Future

Anti-Infective Treatment and Resistance Is Rarely Problematic with Eye Infections

The promise of endogenous and exogenous riboflavin in anti-infection

Contact Info

Product

Resources

About